CVS Health Corp (NYSE: CVS) is back in the spotlight. As of December 6, 2025, CVS stock is trading around $75.60 per share, following a powerful 2025 rally but also a wave of fresh legal settlements, a major goodwill write‑down and renewed questions about its clinic strategy.
At the same time, management has raised 2025 profit guidance, is signaling double‑digit earnings growth in 2026, and Wall Street now sees mid‑teens to low‑20% upside over the next 12 months. [1]
Below is a detailed, news‑driven look at CVS: the latest developments as of December 6, 2025, plus forecasts, risks and key debates investors are watching.
1. Latest CVS Stock News (December 6, 2025)
1.1 New legal settlements hit the headlines
Over the last two weeks, CVS has been at the center of several high‑profile legal and regulatory stories:
- Insulin pen settlement – $37.8 million
On December 2, 2025, CVS agreed to pay $37.76 million to resolve U.S. government allegations that some of its pharmacies improperly dispensed insulin pens and then billed Medicare, Medicaid and other programs for more than patients were prescribed between 2010 and 2020. [2]
Prosecutors said staff sometimes used the maximum allowed days‑supply on claims, enabling earlier refills and higher reimbursements. CVS did not admit liability and said evolving pharmacy benefit practices have improved billing accuracy. [3] - False Claims Act settlement – $18.2 million
On November 17, 2025, the U.S. Department of Justice announced that CVS Pharmacy Inc. will pay $18.2 million to resolve alleged violations of the False Claims Act related to certain pharmacy claims submitted to federal programs. [4] - Caremark Medicare case – nearly $290 million judgment
In August, a federal judge ordered CVS’s pharmacy benefit manager, CVS Caremark, to pay about $289.9 million in damages and penalties after finding that the PBM overcharged Medicare for prescription drugs. The ruling tripled previously awarded damages to $285 million and added roughly $4.9 million in civil penalties. CVS plans to appeal. [5]
These cases add to a separate Department of Justice lawsuit filed in May 2025, which accuses CVS, Humana and Elevance of paying improper kickbacks to Medicare Advantage brokers via eHealth, GoHealth and SelectQuote. [6]
Takeaway for investors:
Legal and compliance risk is now a central part of the CVS investment story. The recent cash settlements are manageable relative to CVS’s size, but the pattern of False Claims Act and Medicare‑related cases reinforces headline and reputational risk, and could influence how regulators treat PBMs and Medicare Advantage plans going forward.
1.2 Analyst upgrades and fresh institutional buying
Despite the legal noise, Wall Street and some institutional investors are leaning more positive on CVS:
- Bernstein raises price target
On December 5, 2025, Bernstein maintained a “Market Perform” rating on CVS but raised its price target from $77 to $86, an 11.7% increase. [7] - Consensus targets move into the high‑80s to low‑90s
- MarketBeat reports that 26 analysts have an average 12‑month target price of about $90.95, with a high of $102 and a low of $72. That implies roughly 20% upside from current levels. [8]
- StockAnalysis shows 18 covering analysts with a “Strong Buy” consensus and an average target of $87.72, also with a high of $102 and low of $70, pointing to around 16% upside. [9]
- CVS highlighted as a high‑yield healthcare pick
Recent coverage from Benzinga and other outlets has grouped CVS with a small set of healthcare names offering above‑market dividend yields plus potential capital appreciation, highlighting it as a value‑oriented income play. [10] - New institutional interest
A filing highlighted by MarketBeat on December 6 shows GeoWealth Management LLC boosted its CVS stake by 638% in Q2, acquiring 13,922 additional shares to reach 16,104 total shares. [11]
Takeaway:
The street’s message is nuanced: CVS is not treated as a “hyper‑growth” story, but rather a value and income name whose integrated healthcare model could drive modest growth and margin recovery from a depressed base.
1.3 Near‑term sentiment: choppy but constructive
Recent technical and trading commentary suggests that:
- CVS’s 2025 rally has left it in a mid‑range trading channel, with some analysts warning of short‑term volatility as the stock digests gains and headlines. [12]
- A discounted cash flow analysis published this week estimates CVS could still be materially undervalued, with one model suggesting upside north of 60% versus intrinsic value, depending on the assumptions used. [13]
In other words: short‑term noise, long‑term value is a common theme among recent analyses.
2. Earnings and Guidance: What Q3 2025 Says About CVS
2.1 Q3 2025: strong underlying business, ugly headline loss
On October 29, 2025, CVS reported third‑quarter results that show a mixed picture:
- Revenue: $102.9 billion, up 7.8% year‑on‑year, driven by strong prescription volumes, higher drug prices, and growth in the Health Care Benefits segment. [14]
- Adjusted EPS:$1.60, up from $1.09 a year earlier – a roughly 47% increase, beating consensus estimates which were around $1.37. [15]
- GAAP results: A GAAP loss of $3.13 per share, mainly due to a $5.7 billion goodwill impairment charge tied to its Health Care Delivery unit, including Oak Street Health primary‑care clinics, partly offset by a gain from deconsolidating Omnicare. [16]
Operationally, CVS continued to generate robust cash:
- Cash flow from operations reached $7.2 billion year‑to‑date, with full‑year guidance raised to $7.5–$8.0 billion. [17]
2.2 Oak Street clinics: scaling back the big bet on primary care
One of the most important strategic shifts revealed in Q3:
- CVS will close 16 underperforming Oak Street Health clinics, around 7% of its footprint, and will not open any new centers in 2026. [18]
The decision follows the large impairment charge, which management tied to slower‑than‑expected returns on the Oak Street and broader care‑delivery strategy. [19]
Investor angle:
CVS is essentially resetting expectations for its clinic business, shifting focus from rapid expansion to optimizing existing locations. That reduces capex pressure and may help margins, but it also tempers the long‑term growth narrative that originally justified the Oak Street acquisition.
2.3 2025 and 2026 guidance: cautious optimism
In the same Q3 update, CVS:
- Raised 2025 adjusted EPS guidance to $6.55–$6.65 per share (from $6.30–$6.40). [20]
- Indicated expectations for double‑digit earnings growth in 2026, even as it absorbs the clinic reset and responds to ongoing medical cost pressures. [21]
On November 10, CVS also announced it will host an Investor Day on December 9, 2025, where management plans to lay out updated strategy and formal 2026 guidance. [22]
What to watch:
Investor Day will be a key catalyst. The market will be looking for:
- More detail on margin recovery, especially in Health Care Benefits and Health Services.
- A roadmap for Oak Street and Signify Health, including how CVS plans to extract value from these assets without overspending.
- Updated capital allocation plans (dividends, buybacks, deleveraging).
3. Dividend and Valuation: CVS as a Value‑and‑Income Play
3.1 Dividend profile: steady and relatively generous
CVS continues to position itself as a dependable dividend payer:
- The company has paid a $0.665 quarterly dividend throughout 2025, declared multiple times during the year. [23]
- That equates to an annualized dividend of about $2.66 per share.
- With CVS stock around $75–76, the current dividend yield is roughly 3.4–3.6%, depending on the precise price used. Several data providers peg the yield in that range. [24]
Given management’s 2025 adjusted EPS guidance of $6.55–$6.65, the payout ratio sits around 40%, leaving room for reinvestment, debt reduction and potential future increases. [25]
Recent analyst commentary frames CVS as offering a solid, well‑covered dividend that looks particularly attractive versus the broader market’s lower yield. [26]
3.2 Valuation: still cheap by historical standards
Using the midpoint of 2025 adjusted EPS guidance ($6.60) and a share price around $75.60, CVS is trading at a forward price‑to‑earnings (P/E) ratio of roughly 11.5x – a discount to many diversified healthcare peers and to the broader S&P 500. (This simple P/E estimate is based on publicly available guidance and the latest quote.) [27]
Additional valuation perspectives:
- One widely cited DCF model suggests CVS could be significantly undervalued, estimating nearly 70% upside from current levels if long‑term cash‑flow assumptions are met. [28]
- Several independent analyses emphasize that CVS’s valuation looks “cheap” relative to its cash generation and dividend, especially if 2026 margin recovery materializes as expected. [29]
Bottom line:
On classic valuation metrics—P/E, dividend yield, and free‑cash‑flow yield—CVS looks more like a contrarian value opportunity than a momentum stock, assuming legal and regulatory risks remain manageable.
4. Wall Street Forecasts for CVS Stock
To summarize current street expectations:
- Ratings:
- 12‑month price targets:
- MarketBeat: average $90.95 (high $102, low $72), implying about 20% upside. [32]
- StockAnalysis: average $87.72 (high $102, low $70), implying around 16% upside. [33]
- Benzinga’s overview lists a consensus target of $86, with Wells Fargo’s recent high at $102 and Deutsche Bank at the low end near $70. [34]
- Growth outlook:
- Management is targeting mid‑single‑digit revenue growth combined with margin expansion, underpinned by its integrated model (insurance + PBM + retail + clinics) and cost synergies from Aetna, Oak Street and Signify Health. [35]
- The official line from Q3 is for double‑digit adjusted EPS growth in 2026, which, if achieved, would make today’s valuation look more compelling. [36]
Key question for investors:
Do you believe CVS can actually deliver the 2026 margin recovery and earnings growth baked into these targets, while absorbing legal settlements and regulatory change?
5. Major Risks CVS Shareholders Should Track
Even bullish analyses on CVS tend to stress several important risks:
- Regulatory and legal exposure
- Ongoing and recent False Claims Act cases (Caremark Medicare overbilling, insulin pen claims, other FCA settlements) highlight heightened legal risk. [37]
- The DOJ lawsuit alleging kickbacks in Medicare Advantage broker arrangements adds additional uncertainty and could prompt tighter rules for MA marketing and compensation. [38]
- Medicare Advantage profitability
- Changing government reimbursement formulas, higher medical costs and stricter oversight make Medicare Advantage a tougher business across the industry. Several recent articles note that CVS’s MA portfolio is facing some of the same headwinds as peers, even as it gains members. [39]
- Primary‑care strategy execution
- The $5.7 billion impairment and decision to shut 16 Oak Street clinics underscore how difficult it is to profitably scale value‑based primary care. [40]
- If margins don’t recover and clinic utilization stays below expectations, investors could question whether CVS overpaid for Oak Street and Signify Health.
- PBM scrutiny and pricing pressure
- CVS’s Caremark unit is under scrutiny from policymakers and competitors, and could face further margin pressure as employers and regulators push for more transparency and lower drug costs. Recent judgments and investigations reinforce the PBM’s high‑stakes environment. [41]
- Execution complexity of an integrated model
- CVS is simultaneously operating a large insurer (Aetna), a PBM, a national retail chain, and a growing—but now rationalizing—network of clinics. Coordinating all of this while keeping customers and regulators satisfied is operationally complex and leaves little room for error.
6. Is CVS Stock a Buy, Hold or Sell Right Now?
From a news and fundamentals standpoint as of December 6, 2025, the CVS thesis looks like this:
Bullish points
- Stronger‑than‑expected Q3 on an adjusted basis, with rising prescriptions and solid Health Care Benefits performance. [42]
- Raised 2025 EPS and cash‑flow guidance, and management signaling double‑digit EPS growth in 2026. [43]
- A forward P/E near 11–12x, coupled with a ~3.5% dividend yield and a payout ratio around 40%, gives CVS the profile of a value‑and‑income compounder, not a fully valued defensive stock. [44]
- Consensus analyst targets in the high‑80s to low‑90s and a generally positive ratings profile suggest Wall Street expects moderate upside from here. [45]
Bearish / cautious points
- A string of False Claims Act cases, Medicare fraud judgments and settlements raises questions about compliance culture and exposes CVS to further financial and reputational damage. [46]
- The $5.7 billion impairment on clinics, and decision to slow expansion, show that part of CVS’s high‑profile “healthcare delivery” strategy is not playing out as originally planned. [47]
- Medicare Advantage, PBM margins and drug pricing reform remain moving targets that can compress profitability just as CVS tries to engineer a margin recovery. [48]
Neutral takeaway (not investment advice):
CVS today looks like a legally noisy but fundamentally solid value stock: inexpensive by earnings and cash flow, with an above‑market yield and a credible—but not risk‑free—plan for 2026 margin recovery. For investors comfortable with regulatory and litigation risk, recent pullbacks and legal headlines may be more of a sentiment overhang than a thesis‑killer, but those same risks make the stock unsuitable for anyone seeking a simple, low‑drama defensive holding.
As always, this article is for informational and news purposes only and does not constitute financial advice. Investors should consider their own objectives, risk tolerance and, ideally, consult a qualified financial adviser before making any decisions about CVS Health stock.
References
1. s206.q4cdn.com, 2. www.reuters.com, 3. www.reuters.com, 4. www.justice.gov, 5. www.reuters.com, 6. www.healthcaredive.com, 7. www.gurufocus.com, 8. www.marketbeat.com, 9. stockanalysis.com, 10. www.benzinga.com, 11. www.marketbeat.com, 12. news.stocktradersdaily.com, 13. finance.yahoo.com, 14. www.cvshealth.com, 15. www.cvshealth.com, 16. investors.cvshealth.com, 17. www.gurufocus.com, 18. www.emarketer.com, 19. www.healthcaredive.com, 20. www.cvshealth.com, 21. www.fiercehealthcare.com, 22. investors.cvshealth.com, 23. investors.cvshealth.com, 24. www.macrotrends.net, 25. s206.q4cdn.com, 26. www.ainvest.com, 27. s206.q4cdn.com, 28. finance.yahoo.com, 29. seekingalpha.com, 30. stockanalysis.com, 31. www.marketbeat.com, 32. www.marketbeat.com, 33. stockanalysis.com, 34. www.benzinga.com, 35. www.indexbox.io, 36. www.fiercehealthcare.com, 37. www.reuters.com, 38. www.healthcaredive.com, 39. www.reuters.com, 40. www.healthcaredive.com, 41. www.reuters.com, 42. www.cvshealth.com, 43. s206.q4cdn.com, 44. www.macrotrends.net, 45. www.marketbeat.com, 46. www.reuters.com, 47. www.healthcaredive.com, 48. www.fiercehealthcare.com
